Drug intelligence / Profile preview

fetal human placental stromal cells

Development stage: Preclinical
Lead developer: Pluri
Modality: Cell Therapies
Administration: Intramuscular, Intraperitoneal

Overview

Fetal human placental stromal cells (f-hPSCs) are a novel cell therapy approach utilizing non-matched, expanded, potent xenogeneic fetal human mesenchymal stromal cells. This cell therapy has demonstrated pro-regenerative and anti-inflammatory effects by responding to host stress and secreting an adequate secretome. It is currently being investigated for the treatment of Inflammatory Bowel Disease (IBD), where it has shown to enhance regenerative processes, reduce inflammation, and improve histological scores in preclinical models.

Beyond the preview

Go deeper on fetal human placental stromal cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fetal human placental stromal cells.

Explore the full profile